aDepartment of Pharmacology, University of Texas Health Science Center at San Antonio

bAddiction Research, Treatment & Training Center of Excellence, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

cDepartment of Pharmacy and Pharmacology, University of Bath, Bath

dCurrent address: School of Life Sciences, University of Bedfordshire, Luton, UK

eDepartment of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA

fCentre for Therapeutic Innovation, University of Bath, Bath, UK

gDepartment of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas

hOrexigen Therapeutics Inc., La Jolla, California, USA

Received 15 January 2022 Accepted as revised 5 May 2022

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website, www.behaviouralpharm.com.

Correspondence to Lisa R. Gerak, PhD, Department of Pharmacology, University of Texas Health Science at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA, E-mail: [email protected]